Wenwang Lang

4PUBLICATIONS
0CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Nanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 26, 2025
Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China.

Wenwang Lang, Jiangbo Wang, Ming Ouyang

|Aug 21, 2025
Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective.

Wenwang Lang, Jiangbo Wang, Haiqing Zhao

|Sep 14, 2024
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.

Wenwang Lang, Qi Ai, Yulong He

|Nov 22, 2023
Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma.

Wenwang Lang, Jiarong Wei, Qinling Jiang

Pageof 1

Frequent Collaborators